These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 33019386)

  • 1. Blood neurofilament light chain in Parkinson disease and atypical parkinsonisms: A protocol for systematic review and meta-analysis.
    Wang H; Wang W; Shi H; Han L; Pan P
    Medicine (Baltimore); 2020 Oct; 99(40):e21871. PubMed ID: 33019386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid and blood levels of neurofilament light chain in Parkinson disease: A protocol for systematic review and meta-analysis.
    Wang H; Wang W; Shi H; Han L; Pan P
    Medicine (Baltimore); 2020 Jul; 99(31):e21458. PubMed ID: 32756166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light chain and α-synuclein RT-QuIC as differential diagnostic biomarkers in parkinsonisms and related syndromes.
    Quadalti C; Calandra-Buonaura G; Baiardi S; Mastrangelo A; Rossi M; Zenesini C; Giannini G; Candelise N; Sambati L; Polischi B; Plazzi G; Capellari S; Cortelli P; Parchi P
    NPJ Parkinsons Dis; 2021 Oct; 7(1):93. PubMed ID: 34635674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
    Marques TM; van Rumund A; Oeckl P; Kuiperij HB; Esselink RAJ; Bloem BR; Otto M; Verbeek MM
    Neurology; 2019 Mar; 92(13):e1479-e1486. PubMed ID: 30814322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study.
    Painous C; Pascual-Diaz S; Muñoz-Moreno E; Sánchez V; Pariente JC; Prats-Galino A; Soto M; Fernández M; Pérez-Soriano A; Camara A; Muñoz E; Valldeoriola F; Caballol N; Pont-Sunyer C; Martin N; Basora M; Tio M; Rios J; Martí MJ; Bargalló N; Compta Y
    Eur Radiol; 2023 Jul; 33(7):4540-4551. PubMed ID: 36773046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Neurofilament Light Chain in Different Types of Dementia.
    Gu L; Shu H; Wang Y; Wang P
    Curr Alzheimer Res; 2023; 20(3):149-160. PubMed ID: 37264656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.
    Wang SY; Chen W; Xu W; Li JQ; Hou XH; Ou YN; Yu JT; Tan L
    J Alzheimers Dis; 2019; 72(4):1353-1361. PubMed ID: 31744001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis.
    Wong YY; Wu CY; Yu D; Kim E; Wong M; Elez R; Zebarth J; Ouk M; Tan J; Liao J; Haydarian E; Li S; Fang Y; Li P; Pakosh M; Tartaglia MC; Masellis M; Swardfager W
    Parkinsonism Relat Disord; 2022 Aug; 101():119-128. PubMed ID: 35760718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.
    Ćwiklińska A; Procyk G; Koziorowski D; Szlufik S
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative susceptibility mapping and blood neurofilament light chain differentiate between parkinsonian disorders.
    Zhang P; Chen J; Cai T; He C; Li Y; Li X; Chen Z; Wang L; Zhang Y
    Front Aging Neurosci; 2022; 14():909552. PubMed ID: 35992605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
    Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
    Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light chain in spinal fluid and plasma in multiple system atrophy: a prospective, longitudinal biomarker study.
    Singer W; Schmeichel AM; Sletten DM; Gehrking TL; Gehrking JA; Trejo-Lopez J; Suarez MD; Anderson JK; Bass PH; Lesnick TG; Low PA
    Clin Auton Res; 2023 Dec; 33(6):635-645. PubMed ID: 37603107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.